| Basics |
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
|
| IPO Date: |
July 24, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.62B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.21 | 2.54%
|
| Avg Daily Range (30 D): |
$0.72 | 2.05%
|
| Avg Daily Range (90 D): |
$0.78 | 2.14%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.54M |
| Avg Daily Volume (30 D): |
1.62M |
| Avg Daily Volume (90 D): |
.96M |
| Trade Size |
| Avg Trade Size (Sh.): |
74 |
| Avg Trade Size (Sh.) (30 D): |
77 |
| Avg Trade Size (Sh.) (90 D): |
64 |
| Institutional Trades |
| Total Inst.Trades: |
6,030 |
| Avg Inst. Trade: |
$2.33M |
| Avg Inst. Trade (30 D): |
$1.9M |
| Avg Inst. Trade (90 D): |
$2.07M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.2M |
| Avg Closing Trade (30 D): |
$3.73M |
| Avg Closing Trade (90 D): |
$3.8M |
| Avg Closing Volume: |
77.85K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-6.99
|
$-1.78
|
$-1.93
|
|
Diluted EPS
|
$-7.01
|
$-1.78
|
$-1.93
|
|
Revenue
|
$ 44.79M
|
$ 12.88M
|
$ 12.46M
|
|
Gross Profit
|
$ 39.07M
|
$ 11.2M
|
$ 10.75M
|
|
Net Income / Loss
|
$ -401.27M
|
$ -103.43M
|
$ -112.02M
|
|
Operating Income / Loss
|
$ -475.59M
|
$ -116.87M
|
$ -127.06M
|
|
Cost of Revenue
|
$ 5.73M
|
$ 1.68M
|
$ 1.7M
|
|
Net Cash Flow
|
$ -161.02M
|
$ 11.84M
|
$ 1.91M
|
|
PE Ratio
|
|
|
|
|
|
|
